Table 6.
Top 10 co-cited references for immunotherapy-TME-related research.
| Rank | Author/Year | Title | Journal | Citations | Type of Article |
|---|---|---|---|---|---|
| 1 | Pardoll, Drew M (2012) | The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer | 1217 | Review |
| 2 | Topalian, Suzanne L (2012) | Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer | New England Journal of Medicine | 1155 | Article |
| 3 | Hanahan, Douglas (2011) | Hallmarks of Cancer: The Next Generation | Cell | 1120 | Review |
| 4 | Hodi, F. Stephen (2010) | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | New England Journal of Medicine | 1020 | Article |
| 5 | Tumeh, Paul C (2014) | PD-1 blockade induces responses by inhibiting adaptive immune resistance | Nature | 906 | Article |
| 6 | Brahmer, Julie R (2012) | Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer | New England Journal of Medicine | 800 | Article |
| 7 | Rizvi, Naiyer A (2015) | Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Science | 757 | Article |
| 8 | Bray, Freddie (2018) | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | CA: A Cancer Journal for Clinicians | 746 | Article |
| 9 | Chen, Daniel S (2013) | Oncology Meets Immunology: The Cancer-Immunity Cycle | Immunity | 654 | Review |
| 10 | Newman, Aaron M (2015) | Robust enumeration of cell subsets from tissue expression profiles | Nature Methods | 648 | Article |